J&J Consumer Business Picks Up, But Analysts See Long Road
This article was originally published in The Tan Sheet
Executive Summary
The consumer business inched up 1% operationally in Q3, including about 6% growth at constant currency in OTC/nutritionals. However, costs associated with the remediation of McNeil OTC facilities are expected to weigh on J&J through most of 2013.
You may also be interested in...
Bapineuzumab Failure Raises More Doubts About Beta Amyloid Approach In Alzheimer’s
As many observers expected, top-line results from a Phase III study show bapineuzumab doesn’t work in carriers of the ApoE4 gene, who are at highest risk for Alzheimer’s disease. An interim analysis of another Phase III study in carriers will now be “expedited,” and other studies of non-carriers will keep going, Pfizer says.
J&J’s Gorsky Promises Prioritization Of OTC Business
Johnson & Johnson’s Q2 was another quarter of flat consumer products growth, with the return of some OTCs to market delayed until 2013. In his quarterly earnings call debut, CEO Alex Gorsky emphasized the firm’s commitment to diversification and restoring the supply of OTC products.
McNeil Remediation Stretches Out, Dragging On J&J Consumer Sales
The latest delay in Johnson & Johnson’s remediation of its McNeil OTC manufacturing pushes back FDA’s review of the Fort Washington, Pa., facility to “late 2013.” The firm’s Q1 results saw the worldwide consumer business fall 2.4% to $3.60 billion, including negative currency exchange effects.